{"id":4527,"date":"2026-02-20T12:57:52","date_gmt":"2026-02-20T09:57:52","guid":{"rendered":"https:\/\/pharmaworlddergi.com\/?p=4527"},"modified":"2026-02-20T12:57:52","modified_gmt":"2026-02-20T09:57:52","slug":"berko-ilac-40-yili-askin-suredir-toplum-sagligina-deger-katiyor","status":"publish","type":"post","link":"https:\/\/pharmaworlddergi.com\/?p=4527","title":{"rendered":"Berko \u0130la\u00e7, 40 Y\u0131l\u0131 A\u015fk\u0131n S\u00fcredir Toplum Sa\u011fl\u0131\u011f\u0131na De\u011fer Kat\u0131yor"},"content":{"rendered":"\n

T\u00fcrk ila\u00e7 sekt\u00f6r\u00fcn\u00fcn ve \u00fclke ekonomisinin s\u00fcrd\u00fcr\u00fclebilir olu\u015fumuna 40 y\u0131l\u0131 a\u015fk\u0131n s\u00fcredir katk\u0131 sa\u011flayan Berko \u0130la\u00e7\u2019\u0131n CEO\u2019su Ecz. Bar\u0131\u015f \u00d6zyurtlu ile T\u00fcrkiye\u2019de yerli ila\u00e7 \u00fcretiminin dinamikleri ve Berko \u0130la\u00e7\u2019\u0131n 40 y\u0131ll\u0131k ba\u015far\u0131l\u0131 yolculu\u011fu \u00fczerine bir sohbet ger\u00e7ekle\u015ftirdik. <\/strong><\/strong><\/p>\n\n\n\n

Berko \u0130la\u00e7\u2019\u0131n i\u00e7inden yeti\u015fen bir lider olarak tan\u0131yoruz sizi. Bize biraz kendinizden ve CEO\u2019lu\u011fa giden s\u00fcre\u00e7teki ser\u00fcveninizden bahseder misiniz?<\/strong><\/p>\n\n\n

\n
\"\"<\/figure><\/div>\n\n\n

Eczac\u0131l\u0131k fak\u00fcltesi mezunuyum. Meslek hayat\u0131ma 2002 y\u0131l\u0131nda Berko \u0130la\u00e7\u2019ta t\u0131bbi tan\u0131t\u0131m temsilcisi olarak ba\u015flad\u0131m. Bu g\u00f6revi alt\u0131 ay s\u00fcrd\u00fcrd\u00fckten sonra, alt\u0131 ay da b\u00f6lge y\u00f6neticisi olarak devam ettim ve sonras\u0131nda b\u00f6lge m\u00fcd\u00fcr\u00fc olarak g\u00f6rev ald\u0131m. 2008-2013 y\u0131llar\u0131 aras\u0131nda eczane eczac\u0131l\u0131\u011f\u0131 yapt\u0131m ve ayn\u0131 d\u00f6nemde Berko \u0130la\u00e7\u2019a dan\u0131\u015fman eczac\u0131 olarak hizmet vermeyi s\u00fcrd\u00fcrd\u00fcm. 2014-2016 y\u0131llar\u0131 aras\u0131 genel m\u00fcd\u00fcr yard\u0131mc\u0131s\u0131, 2016 y\u0131l\u0131nda ise genel m\u00fcd\u00fcr oldum. 2 y\u0131ld\u0131r da CEO olarak g\u00f6revimi s\u00fcrd\u00fcr\u00fcyorum.<\/p>\n\n\n\n

D\u00f6rt y\u0131l Diyarbak\u0131r Eczac\u0131 Odas\u0131\u2019nda y\u00f6netim kurulu \u00fcyeli\u011fi, iki y\u0131l TEB (T\u00fcrk Eczac\u0131lar\u0131 Birli\u011fi) delegeli\u011fi yapt\u0131m. 2025-2027 d\u00f6neminde TEB delegeli\u011fi g\u00f6revine devam ediyorum. \u0130VEK M\u00fctevelli Heyet \u00dcyesiyim ve \u0130VEK \u0130la\u00e7 End\u00fcstrisi ve Teknolojileri Komisyon Ba\u015fkanl\u0131\u011f\u0131n\u0131 y\u00fcr\u00fct\u00fcyorum. 2023-2025 d\u00f6nemi TEB delegeli\u011fi g\u00f6revine devam ediyorum ve ayn\u0131 zamanda DE\u0130K (D\u0131\u015f Ekonomik \u0130li\u015fkiler Kurulu)Sa\u011fl\u0131k \u0130\u015f Konseyi\u2019nin yeni y\u00fcr\u00fctme kurulunda yer al\u0131yorum.<\/p>\n\n\n\n

2014 y\u0131l\u0131nda genel m\u00fcd\u00fcr yard\u0131mc\u0131s\u0131 olarak merkez ofise geldi\u011fim g\u00fcnden bug\u00fcne ciddi bir ivme yakalad\u0131k. 2015 y\u0131l\u0131nda 105 milyon dolar civar\u0131nda olan ciromuz bug\u00fcn 5 milyar TL\u2019ye ula\u015ft\u0131. 21 milyon kutu \u00fcretimimiz varken, \u015fu an 90 milyon kutular\u0131 ge\u00e7mi\u015f durumday\u0131z. Yeni yat\u0131r\u0131mlar\u0131m\u0131zla 150 milyon kutuya ula\u015fmay\u0131 hedefliyoruz. T\u00fcm bu geli\u015fimin bir par\u00e7as\u0131 olmak benim i\u00e7in b\u00fcy\u00fck bir mutluluk ve gurur kayna\u011f\u0131.<\/p>\n\n\n\n

T\u00fcrkiye\u2019deki ila\u00e7 fiyatland\u0131rma politikalar\u0131 ve ruhsatland\u0131rma s\u00fcre\u00e7lerinde ya\u015fanan gecikmeler, yerli bir \u00fcretici olarak sizleri nas\u0131l etkiliyor?<\/strong><\/p>\n\n\n\n

Yerli \u00fcretim yapan firmalar\u0131n kutu baz\u0131nda sat\u0131\u015flar\u0131 neredeyse pazar\u0131n %89\u2019ucivar\u0131nda. Ancak de\u011fer baz\u0131nda de\u011ferlendirildi\u011finde bu oran %60\u2019lara yakla\u015fam\u0131yor. Bunun bir sebebi, katma de\u011feri y\u00fcksek \u00fcr\u00fcnler \u00fcretemiyor olu\u015fumuz. Di\u011fer bir sebep de jenerik \u00fcr\u00fcn\u00fc \u00fcretti\u011fimiz anda fiyat\u0131n ba\u015flang\u0131\u00e7tan itibaren d\u00fc\u015fmesi; ard\u0131ndan geri \u00f6deme s\u00fcrecinde yeniden iskonto yapmak durumunda kalmam\u0131z. B\u00f6ylece orijinal \u00fcr\u00fcn\u00fcn yar\u0131s\u0131 de\u011ferine kadar inmi\u015f oluyoruz.<\/p>\n\n\n\n

T\u00fcrkiye\u2019deki fiyatland\u0131rma sistemi yerli \u00fcreticileri olduk\u00e7a zorluyor. Fiyatlar, Avrupa \u00fclkelerinin %17-23\u2019\u00fc seviyesinde. D\u00fcnyada en ucuz fiyatlar Hindistan\u2019da, ancak \u015fu an neredeyse T\u00fcrkiye\u2019de de baz\u0131 \u00fcr\u00fcnler Hindistan\u2019dan bile d\u00fc\u015f\u00fck kalm\u0131\u015f durumda. Fiyatlar\u0131n bu kadar a\u015fa\u011f\u0131da tutulmas\u0131 \u00fcreticiyi olumsuz y\u00f6nde etkiliyor. Yeni yat\u0131r\u0131mlara y\u00f6nelemiyoruz; \u00fcretim kapasitemizi art\u0131rmak, fabrikaya yat\u0131r\u0131m yapmak zorla\u015f\u0131yor ve Ar-Ge i\u00e7in ayr\u0131lan b\u00fct\u00e7e de do\u011fal olarak k\u0131s\u0131lmak durumunda kal\u0131yor.<\/p>\n\n\n\n

Berko \u0130la\u00e7 Berat Beran \u0130la\u00e7\u2019la birlikte t\u00fcm ila\u00e7 sekt\u00f6r\u00fc i\u00e7erisinde kutu sat\u0131\u015f\u0131nda T\u00fcrkiye\u2019de 10. s\u0131rada yer al\u0131yor. Ciromuz ise bu y\u0131l\u0131 baz al\u0131rsak 5 milyar TL civar\u0131nda. Kutu sat\u0131\u015f\u0131m\u0131z de\u011ferlendirildi\u011finde bu cironun 8 milyar dolar\u0131n \u00fczerinde olmas\u0131 gerekirdi, ancak fiyatland\u0131rma politikalar\u0131 nedeni ile kutu sat\u0131\u015f\u0131m\u0131z ve ciromuz do\u011fru orant\u0131l\u0131 de\u011fil. Bu durum da fiyatland\u0131rma politikalar\u0131n\u0131n bir sonucu olarak kar\u015f\u0131m\u0131za \u00e7\u0131k\u0131yor.<\/p>\n\n\n\n

\u0130la\u00e7 \u00fcretimi y\u00fcksek teknoloji gerektirir, bu teknolojiye yat\u0131r\u0131m yapabilmek i\u00e7in de firmalar\u0131n yeterli k\u00e2rl\u0131l\u0131\u011fa ula\u015fmas\u0131 gerekir. T\u00fcrkiye\u2019de devletin uygulad\u0131\u011f\u0131 bu fiyat politikas\u0131 ile ila\u00e7ta gelece\u011fi in\u015fa etmek g\u00fc\u00e7 hale geliyor.<\/p>\n\n\n\n

Ruhsatland\u0131rma s\u00fcre\u00e7leri \u00fclkemizde olduk\u00e7a uzun s\u00fcr\u00fcyor. Bunu do\u011frudan T\u0130TCK ile ili\u015fkilendirmek de belki de \u00e7ok do\u011fru de\u011fil. T\u00fcrkiye \u0130la\u00e7 ve T\u0131bbi Cihaz Kurumu (T\u0130TCK) 2018 y\u0131l\u0131nda Uluslararas\u0131 \u0130la\u00e7 Denetim Birli\u011fi\u2019ne (PIC\/S) ve 2020 y\u0131l\u0131nda ICH\u2019e tam \u00fcye olarak ruhsatland\u0131rma, klinik ara\u015ft\u0131rmalar ve farmakovijilans gibi faaliyetlerinde uluslararas\u0131 standartlar\u0131 kar\u015f\u0131lad\u0131\u011f\u0131n\u0131 tescil ettirmi\u015ftir. Son olarak 2023 y\u0131l\u0131nda T\u0130TCK D\u00fcnya Sa\u011fl\u0131k \u00d6rg\u00fct\u00fc taraf\u0131ndan listelenen ulusal ila\u00e7 otoritesi olmu\u015ftur. Bu gerekliliklere ila\u00e7 firmalar\u0131n\u0131n biraz daha h\u0131zl\u0131 adapte olmas\u0131 ruhsat s\u00fcrelerinin h\u0131zlanmas\u0131n\u0131 sa\u011flayabilir. COVID d\u00f6neminde biriken dosyalar da bu gecikmede \u015fu an i\u00e7in etkili oluyor. Yakla\u015f\u0131k 1.800 adet ruhsat ba\u015fvuru birikmi\u015f durumunda, y\u0131ll\u0131k kapasitenin 500 oldu\u011funu d\u00fc\u015f\u00fcn\u00fcrsek, hi\u00e7 yeni ba\u015fvuru gelmese dahi biriken ba\u015fvurular\u0131n ruhsatlar\u0131n\u0131n \u00e7\u0131kmas\u0131 yakla\u015f\u0131k \u00fc\u00e7 y\u0131l\u0131 bulacakt\u0131r. Bu s\u00fcrecin bu kadar uzun olmas\u0131 hem yerli hem de uluslararas\u0131 firmalar i\u00e7in elbette zorlay\u0131c\u0131. Bizim de ruhsat ba\u015fvurunda bulundu\u011fumuz ve \u015fu an ruhsatlar\u0131n\u0131n \u00e7\u0131kmas\u0131n\u0131 bekledi\u011fimiz \u00fcr\u00fcnlerimiz var.<\/p>\n\n\n\n

Berko \u0130la\u00e7\u2019\u0131n portf\u00f6y\u00fcnde h\u00e2lihaz\u0131rda ka\u00e7 \u00fcr\u00fcn bulunuyor?<\/strong><\/p>\n\n\n\n

Yakla\u015f\u0131k 110 civar\u0131nda \u00fcr\u00fcn\u00fcm\u00fcz bulunuyor. Bunlar\u0131n 60 kadar\u0131n\u0131 aktif olarak \u00fcretiyoruz, kalan\u0131n\u0131 ise hem i\u00e7 hem d\u0131\u015f pazar i\u00e7in ihtiyaca binaen \u00fcretiyoruz. Baz\u0131 \u00fcr\u00fcnlerin ise \u00fcretimini biz ger\u00e7ekle\u015ftiriyoruz fakat sat\u0131\u015f, pazarlama ve da\u011f\u0131t\u0131m faaliyetleri i\u00e7in farkl\u0131 firmalarla anla\u015fmalar yap\u0131yoruz.<\/p>\n\n\n\n

Berko \u0130la\u00e7\u2019\u0131n kronik ila\u00e7 pazar\u0131na girmek \u00fczere yapt\u0131\u011f\u0131 yat\u0131r\u0131mlardan s\u00f6z eder misiniz?<\/strong><\/p>\n\n\n\n

A\u011fr\u0131 kesiciler, vitamin-mineral gruplar\u0131n\u0131n yer ald\u0131\u011f\u0131 akut pazar\u0131ndaki g\u00fc\u00e7l\u00fc konumumuzu kronik pazara da ta\u015f\u0131ma karar\u0131 ald\u0131k. Yat\u0131r\u0131mlar\u0131m\u0131z\u0131 Tip 1 ve Tip 2 diyabet tedavisinde kullan\u0131lacak \u00fcr\u00fcnler \u00fczerine yo\u011funla\u015ft\u0131rd\u0131k.<\/p>\n\n\n\n

Bunun d\u0131\u015f\u0131nda bir biyoteknolojik \u00fcr\u00fcn konusunda bir anla\u015fmaya imza att\u0131k. Ayr\u0131ca steril hormon \u00fcr\u00fcnlerine y\u00f6nelik bir yat\u0131r\u0131m\u0131m\u0131z bulunuyor. \u0130ki antibiyotik ise \u015fu an portf\u00f6y\u00fcm\u00fcze eklenmi\u015f durumda. Diyabet alan\u0131ndaki \u00fcr\u00fcnler i\u00e7in ruhsat ba\u015fvurular\u0131n\u0131 yapm\u0131\u015f bulunuyoruz ve b\u00fcy\u00fck ihtimalle 2027 y\u0131l\u0131nda bu \u00fcr\u00fcnleri pazara sunmu\u015f olaca\u011f\u0131z. Ayr\u0131ca nadir hastal\u0131klarla ilgili proje \u00e7al\u0131\u015fmalar\u0131na da ba\u015flad\u0131\u011f\u0131m\u0131z\u0131 s\u00f6yleyebilirim.<\/p>\n\n\n\n

Berko ila\u00e7 \u015fu an d\u0131\u015f pazarlarda hangi \u00fclkelerde varl\u0131k g\u00f6steriyor? Kronik ila\u00e7 pazar\u0131na da girecek olman\u0131zla birlikte d\u0131\u015f pazarlardaki hedefleriniz neler olacak?<\/strong><\/p>\n\n\n\n

T\u00fcrkiye ila\u00e7 pazar\u0131nda g\u00fc\u00e7l\u00fc bir marka olan Berko \u0130la\u00e7, bir d\u00fcnya markas\u0131 olma yolunda emin ad\u0131mlarla ilerliyor. OTC \u00fcr\u00fcnlerde d\u0131\u015f pazarlarda varl\u0131k g\u00f6stermek kronik \u00fcr\u00fcnlere g\u00f6re daha zor. \u015eu an Irak, Azerbaycan, Vietnam, Yemen, Suudi Arabistan Krall\u0131\u011f\u0131 ve Balkan \u00fclkeleri olmak \u00fczere 18 kadar \u00fclkeye ihracat ger\u00e7ekle\u015ftiriyoruz. Kardiyovask\u00fcler \u00fcr\u00fcnler, diyabet \u00fcr\u00fcnleri ve antibiyotiklerde d\u0131\u015f pazarlarda talebin y\u00fcksek oldu\u011funu s\u00f6yleyebilirim. Dolay\u0131s\u0131yla kronik ila\u00e7 pazar\u0131na giri\u015fimiz ile birlikte ihracat hacmimizi de art\u0131rmay\u0131 hedefliyoruz.<\/p>\n\n\n\n

Berko \u0130la\u00e7\u2019\u0131n Ar-Ge \u00e7al\u0131\u015fmalar\u0131ndan biraz bahseder misiniz?<\/strong><\/p>\n\n\n\n

2018 y\u0131l\u0131nda Ar-Ge belgesi almaya hak kazanan Berko \u0130la\u00e7 Ar-Ge Merkezi\u2019nde, her y\u0131l yakla\u015f\u0131k 20 yeni \u00fcr\u00fcn projesi geli\u015ftiriliyor. Y\u00fcksek lisans ve doktora derecesine sahip eczac\u0131, kimyager ve kimya m\u00fchendislerinden olu\u015fan 35 ki\u015filik ara\u015ft\u0131rmac\u0131 kadromuz; g\u00fcncel teknolojiyle donat\u0131lm\u0131\u015f laboratuvarlar\u0131m\u0131z ve kapsaml\u0131 ekipman altyap\u0131m\u0131zla birlikte, Berko Ar-Ge Merkezi\u2019nde katma de\u011feri y\u00fcksek ve yenilik\u00e7i \u00fcr\u00fcnler geli\u015ftirmek \u00fczere \u00e7al\u0131\u015fmalar\u0131n\u0131 s\u00fcrd\u00fcr\u00fcyor.<\/p>\n\n\n\n

\u00dcretim tesisinizden ve y\u0131ll\u0131k \u00fcretim kapasitenizden s\u00f6z eder misiniz?<\/strong><\/p>\n\n\n\n

21.500 m2<\/sup> kapal\u0131 alana sahip Berko \u0130la\u00e7 \u00dcretim Tesisleri\u2019nde bu y\u0131l yakla\u015f\u0131k 90 milyon kutu \u00fcretim ger\u00e7ekle\u015ftirildi. Bunun 70 milyonu bizim kendi \u00fcr\u00fcnlerimizden olu\u015furken, 20 milyon kadar\u0131 da fason \u00fcretti\u011fimiz \u00fcr\u00fcnlerden olu\u015fuyor.<\/p>\n\n\n\n

Berko \u0130la\u00e7\u2019\u0131n \u0130K stratejilerinin temelinde nas\u0131l bir anlay\u0131\u015f var? \u00c7al\u0131\u015fanlar rahatl\u0131kla \u00fcst y\u00f6netim ile direkt ileti\u015fime ge\u00e7ebiliyor mu?<\/strong><\/p>\n\n\n\n

\u0130K yakla\u015f\u0131m\u0131m\u0131z\u0131n temelinde insana de\u011fer vermek var. \u0130nsanlar bu de\u011feri hissettiklerinde \u015firkete ba\u011fl\u0131l\u0131k ve aidiyet duygusu da bununla birlikte geli\u015fiyor. \u015eirketimizde bu aidiyet duygusunun olduk\u00e7a y\u00fcksek oldu\u011funu rahatl\u0131kla s\u00f6yleyebilirim.<\/p>\n\n\n\n

Kendi ad\u0131ma, CEO olarak kap\u0131m herkese a\u00e7\u0131kt\u0131r. Herkes rahatl\u0131kla gelip benimle fikirlerini payla\u015fabilir, zaman\u0131m elverdi\u011fi \u00f6l\u00e7\u00fcde dinlemeye gayret g\u00f6steririm. Bu yakla\u015f\u0131m, \u015firket i\u00e7inde t\u00fcm \u00e7al\u0131\u015fanlara olumlu \u015fekilde yans\u0131yor elbette.<\/p>\n\n\n\n

\u00d6n\u00fcm\u00fczdeki 5 y\u0131l i\u00e7inde hedefleriniz nelerdir?<\/strong><\/p>\n\n\n\n

Hedefim, orgazisasyon yap\u0131s\u0131n\u0131n ve yap\u0131da yer alan t\u00fcm departman \u00e7al\u0131\u015fanlar\u0131n\u0131n verimlili\u011fini art\u0131rmak \u015feklinde. \u0130lave olarak yenilik\u00e7i ve katma de\u011feri daha y\u00fcksek \u00fcr\u00fcnleri, T\u00fcrkiye ila\u00e7 pazar\u0131na sunma \u00e7al\u0131\u015fmalar\u0131m\u0131z\u0131 s\u00fcrd\u00fcrece\u011fiz. Sat\u0131\u015flar\u0131m\u0131z\u0131 kar\u015f\u0131lamak \u00fczere \u00fcretim tesislerimizin kapasitesini ve verimlili\u011fini art\u0131rmaya devam edece\u011fiz. Yeni \u00fcr\u00fcnlerimizle birlikte d\u0131\u015f pazarlarda etkinli\u011fimizi ve d\u0131\u015f ticaret hacmimizi art\u0131raca\u011f\u0131z.<\/p>\n\n\n\n

Son olarak buradan karar vericilere buradan ne mesaj vermek istersiniz?<\/strong><\/p>\n\n\n\n

Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131 ve SGK, ila\u00e7 fiyatlar\u0131n\u0131n d\u00fc\u015f\u00fck kald\u0131\u011f\u0131 konusunda san\u0131r\u0131m bizlerle ayn\u0131 d\u00fc\u015f\u00fcncedeler. Ancak Hazine ve Maliye Bakanl\u0131\u011f\u0131\u2019n\u0131n sa\u011fl\u0131kta uygulad\u0131\u011f\u0131 politikalarla ila\u00e7 b\u00fct\u00e7esi son d\u00f6nemlerde biraz geride kal\u0131yor. Ge\u00e7mi\u015fte daha az kutu sat\u0131\u015f\u0131 yaparken, \u015fu an daha \u00e7ok kutu sat\u0131\u015f\u0131 yapmam\u0131za ra\u011fmen GSYH\u2019den ald\u0131\u011f\u0131m\u0131z pay, ge\u00e7mi\u015f y\u0131llarda %1,2 seviyelerindeyken %0,68\u2019e d\u00fc\u015fm\u00fc\u015f durumdad\u0131r. Bu durum, ila\u00e7 fiyatlar\u0131 ve geri \u00f6deme politikalar\u0131n\u0131n bizleri ne \u00f6l\u00e7\u00fcde zorlad\u0131\u011f\u0131n\u0131 g\u00f6steren bir tablodur. Maliye Bakanl\u0131\u011f\u0131\u2019n\u0131n sa\u011fl\u0131k alan\u0131nda, \u00f6zellikle ilaca y\u00f6nelik politikalar\u0131n\u0131 g\u00f6zden ge\u00e7irmesini ve bu alana ayr\u0131lan b\u00fct\u00e7e oran\u0131n\u0131n, bizim \u00e7ok alt\u0131nda kald\u0131\u011f\u0131m\u0131z OECD \u00fclkelerinde ki\u015fi ba\u015f\u0131 ila\u00e7 sat\u0131\u015f\u0131 ile GSYH i\u00e7indeki pay\u0131 ifade eden %1,2 ortalamas\u0131na yak\u0131n seviyelere \u00e7ekilmesini bekliyoruz. Mevcut olumsuz politikalar\u0131n devam etmesi halinde, uzun y\u0131llar boyunca b\u00fcy\u00fck \u00e7aba ve emekle bug\u00fcnk\u00fc seviyesine ula\u015fan ila\u00e7 end\u00fcstrisi gelece\u011fini sa\u011fl\u0131kl\u0131 bi\u00e7imde kurgulamakta zorlanacak ve geride kalma riskiyle kar\u015f\u0131 kar\u015f\u0131ya olacakt\u0131r. Bu durum ise hastalar\u0131n ilaca eri\u015fimi a\u00e7\u0131s\u0131ndan ciddi ve olumsuz sonu\u00e7lar do\u011furabilecektir.<\/p>\n","protected":false},"excerpt":{"rendered":"

T\u00fcrk ila\u00e7 sekt\u00f6r\u00fcn\u00fcn ve \u00fclke ekonomisinin s\u00fcrd\u00fcr\u00fclebilir olu\u015fumuna 40 y\u0131l\u0131 a\u015fk\u0131n s\u00fcredir katk\u0131 sa\u011flayan Berko \u0130la\u00e7\u2019\u0131n CEO\u2019su Ecz. Bar\u0131\u015f \u00d6zyurtlu ile T\u00fcrkiye\u2019de yerli ila\u00e7 \u00fcretiminin dinamikleri ve Berko \u0130la\u00e7\u2019\u0131n 40 y\u0131ll\u0131k ba\u015far\u0131l\u0131 yolculu\u011fu \u00fczerine bir sohbet ger\u00e7ekle\u015ftirdik. <\/p>\n","protected":false},"author":1,"featured_media":4528,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[48,42],"tags":[],"_links":{"self":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/4527"}],"collection":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4527"}],"version-history":[{"count":1,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/4527\/revisions"}],"predecessor-version":[{"id":4530,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/4527\/revisions\/4530"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/media\/4528"}],"wp:attachment":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4527"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4527"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4527"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}